SAA2 and COVID-19: At the present moment, to our knowledge, there are no published data on SAA as a biomarker of COVID-19 severity in patients with IRD, so future studies should explore the clinical relevance of SAA as a biomarker in the new era of coexistence of IRD patients and SARS-CoV-2.